Seeing Is Believing
Currently out of the existing stock ratings of Matthew Andrews, 23 are a BUY (92%), 2 are a HOLD (8%).
Analyst Matthew Andrews, currently employed carries an average stock price target met ratio of 63.89% that have a potential upside of 31.98% achieved within 136 days. Previously, Matthew Andrews worked at JEFFERIES.
Matthew Andrews’s has documented 51 price targets and ratings displayed on 6 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on SPPI, Spectrum Pharmaceuticals at 06-Sep-2018.
Analyst best performing recommendations are on SPPI (SPECTRUM PHARMACEUTICALS).
The best stock recommendation documented was for SPPI (SPECTRUM PHARMACEUTICALS) at 9/25/2017. The price target of $13 was fulfilled within 3 days with a profit of $3.16 (32.11%) receiving and performance score of 107.05.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$2
$-5.5 (-73.33%)
$18
6 years 3 months 8 days ago
(13-Aug-2018)
3/4 (75%)
$0.34 (20.48%)
130
Hold
$2
$-5.5 (-73.33%)
$30
6 years 3 months 11 days ago
(10-Aug-2018)
1/3 (33.33%)
$14.2 (165.52%)
27
What Year was the first public recommendation made by Matthew Andrews?